Primary care physicians face a persistent challenge distinguishing viral from bacterial respiratory infections, leading to unnecessary antibiotic prescriptions that fuel resistance while providing no patient benefit. This diagnostic uncertainty has made rapid, accurate viral testing a critical missing piece in routine medical practice.
A pilot study across seven New Zealand clinics tested multi-viral rapid antigen point-of-care tests on 1,754 patients with acute respiratory symptoms during winter 2023. The device detected multiple respiratory viruses simultaneously with results available within minutes, replacing COVID-19-only testing. Among tested patients, 14% showed positive results for at least one virus, with two-thirds of prescribing physicians reporting the results directly influenced their antibiotic decisions and 12% avoided hospital referrals based on viral confirmation.
This represents a meaningful step toward precision medicine in primary care, where diagnostic uncertainty drives much of the antibiotic overuse contributing to antimicrobial resistance. The technology addresses a fundamental gap between expensive laboratory PCR testing and clinical guesswork that has persisted for decades. However, the study's observational design cannot definitively prove causation between testing and prescribing changes, and the 14% positive rate suggests many respiratory infections remain undiagnosed even with expanded viral panels. The real test will be whether such point-of-care diagnostics can demonstrate measurable reductions in antibiotic resistance patterns and healthcare costs when implemented at scale across diverse healthcare systems.